Terran Biosciences Announces Licensing Agreement with Sanofi

On April 21, 2022 Terran Biosciences, Inc. ("Terran"), a biotechnology platform company dedicated to the development of transformational therapies for neurological and psychiatric diseases, reported that has entered into an agreement with Sanofi SA ( " Sanofi") for exclusive worldwide rights to develop and commercialize two late-stage SNC portfolio assets (Press release, Sanofi, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These therapies generated four investigational new drug (IND) applications and more than 104 clinical studies involving more than 15,000 subjects in various CNS indications.

Terran plans to rapidly advance the development of these actives for neurological and psychiatric indications, including several novel applications where there is a high unmet medical need. This transaction represents the next key stage in the development of these promising assets.

The deal included an upfront payment, as well as typical milestones and royalties based on success. Specific financial terms of the deal were not disclosed.

"We are grateful to the team at Sanofi for entrusting us with the continued development of these late-stage therapies, which we believe have the potential to transform the paradigm of neuropsychiatry," said Dr. Sam Clark , Founder and CEO of Terran.

Inhibikase Therapeutics to Participate at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference

On April 21, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, reported that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will participate in a fireside chat at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022 at 2:30pm ET (Press release, Inhibikase Therapeutics, APR 21, 2022, View Source;ophthalmology-conference-301530237.html [SID1234612882])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company’s website, www.inhibikase.com. An archived replay of the webcast will be available for approximately 30 days. In addition, the Company recently hosted a virtual Key Opinion Leader investor event on April 20, 2022. A replay of the event can be accessed here.

Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

On April 21, 2022 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, reported that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial markets close (Press release, Dynavax Technologies, APR 21, 2022, https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5-2022-301526392.html [SID1234612881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dynavax will host a conference call and live audio webcast on Thursday, May 5, 2022 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4282730. A replay of the webcast will be available for 30 days following the live event.

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5

On April 21, 2022 Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, reported that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update (Press release, Eiger Biopharmaceuticals, APR 21, 2022, https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-first-quarter-2022-financial-results-and-business-update-on-thursday-may-5-301530543.html [SID1234612880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed webcast of the call will be available through the company’s website at www.eigerbio.com. To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 2392544. The webcast will be archived and available for replay for at least 90 days after the event.

ITM announces symposium and presence at the 60th Annual Meeting of the German Society for Nuclear Medicine in Leipzig

On April 21, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported its participation in the annual meeting of the German Society for Nuclear Medicine from April 27-30, 2022 (Press release, ITM Isotopen Technologien Munchen, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612876]). The conference also represents the 60th anniversary congress of the society and will take place as a hybrid event online and in Leipzig. ITM will host a lunchtime symposium on April 28 on Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective and will also showcase its precision oncology product portfolio at a booth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of ITM’s symposium, Prof. Wolfgang Wadsak, Head of Medical Radiochemistry and Biomarker Development in the Clinical Department for Nuclear Medicine at the University Hospital Vienna , will talk about the production of radiopharmaceuticals for direct application in the field of cancer medicine in clinics and as an essential component and innovation driver in nuclear medicine to speak. Neil Quigley, Global Product Manager, ITM , will present the latest developments and potential indications in the field of targeted radionuclide therapy using the alpha emitter Actinium-225. This topic is supplemented by a lecture by Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, on development opportunities for the innovative radioisotope actinium-225 and on the worldwide supply security of clinics with the established, high-purity medical radioisotope nca lutetium-177 (no-carrier-added). The symposium is part of the official conference program and will take place on April 28, 2022 from 12:30 pm to 1:30 pm in Hall 2 of the congress building.

"We are pleased to complement the scientific conference program with our symposium. The manufacturing of radiopharmaceuticals in clinics is an essential prerequisite to be able to offer cancer patients targeted radionuclide therapies, while the industry develops ready-to-use radiopharmaceuticals," says Steffen Schuster, CEO of ITM . "With our research and development of precision oncological diagnostics and therapeutics for various cancer indications as well as our current product portfolio of medical radioisotopes and radiolabeling equipment, we want to contribute to giving patients worldwide access to targeted cancer therapies that have the potential to improve treatment outcomes and quality of life."

At booth (#A6) in the conference’s industrial exhibition, ITM will present its proprietary portfolio of high-quality medical radioisotopes, as well as all the equipment needed for manufacturing and quality control of radiopharmaceuticals.

– end –

ITM’s research and development activities in the field of precision oncology

In addition to ITM’s central position in the development, production and distribution of medical radioisotopes and radiolabeling equipment, ITM is developing its own broad pipeline of diagnostic and therapeutic radiopharmaceuticals for various cancer indications. ITM’s lead candidate ITM-11 for the treatment of neuroendocrine tumors of gastroentero-pancreatic origin (GEP-NETs) is currently in two phase III studies, COMPETE and COMPOSE. ITM recently announced the successful completion of patient enrollment for the COMPETE trial evaluating ITM-11 for grade 1 and 2 GEP-NETs . In COMPOSE, ITM-11 will be studied for grade 2 and 3 GEP-NETs in order to evaluate ITM-11 for a broader GEP-NET indication.

Targeted radionuclide therapy

Targeted radionuclide therapy is a new form of cancer therapeutics that aim to irradiate the tumor directly while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are made by combining a therapeutic radioisotope with a targeting molecule (eg, peptide, antibody, small molecule) that can accurately recognize tumor cells and bind to tumor-specific features such as receptors on the surface of the tumor cells. The radioisotope accumulates at the tumor and decays, releasing a small amount of ionizing radiation capable of destroying tumor tissue. The high-precision localization enables targeted treatment with potentially minimal effects on the surrounding healthy tissue.